Key Takeaways
Long-acting therapeutics can extend dosing intervals from weeks to months through depots, implants, molecular engineering, and durable biological mechanisms.
HIV treatment and prevention provide some of the strongest evidence that long-acting therapies can change treatment paradigms, not just reduce missed doses.
In psychiatry, long-acting formulations may support treatment continuity, but they do not automatically improve clinical outcomes.
Oncology and chronic disease applications show how sustained delivery can maintain endocrine suppression, lower LDL cholesterol, and reduce frequent self-administration.
Successful long-acting product development requires balancing duration with drug loading, injection volume, release control, reversibility, manufacturability, and patient needs.
From Missed Doses to Treatment Redesign
Long-acting therapeutics are often discussed primarily as a response to nonadherence. Extending the interval between doses can reduce the number of times a patient must remember, prepare, or decide to take a medicine, making treatment less dependent on daily behavior. That rationale remains important, particularly in diseases that require sustained therapy over months or years. It also captures only part of what long-acting approaches can accomplish.
A formulation that remains active for weeks or months can alter the structure of treatment itself. It may shift administration from the home to a clinic, make receipt of therapy directly observable, create a longer window of protection against infection, or maintain a biological effect without repeated self-administration. In some settings, the goal is to sustain concentrations of a drug released gradually from a depot. In others, molecular engineering extends circulation time or pharmacologic activity, allowing a therapy to function over a longer interval without relying on a conventional controlled-release formulation.
The category therefore includes several distinct product architectures. Long-acting injectable systems may use suspensions, biodegradable microspheres, or in situ–forming depots, while implantable systems can release a drug through diffusion, material erosion, or a combination of both. Other therapies achieve extended activity through changes to the drug molecule or mechanism rather than through a delivery matrix. These approaches share an extended dosing interval, but they present different requirements for dose loading, administration, manufacturing, monitoring, and reversibility.1,2
This broader view helps explain why the field is expanding across treatment areas with very different clinical needs. In infectious disease, long-acting therapies can extend prevention as well as treatment. In psychiatry, they can provide greater certainty that a scheduled dose was administered, although that does not guarantee improved outcomes. In oncology, depot products can sustain hormonal or endocrine interventions over several months. In cardiovascular and metabolic disease, durable molecular mechanisms and extended half-lives can reduce the frequency of therapies that would otherwise require daily or more frequent administration.
The opportunity extends beyond making an existing regimen easier to follow. Long-acting therapeutics can change when treatment occurs, who administers it, how long its effects persist, and what clinical infrastructure surrounds it. Realizing that opportunity requires developers to define the purpose of duration early. A product designed for six months of infectious-disease prevention presents different demands from a three-month psychiatric injection, a depot oncology therapy, or a weekly insulin. The value of a longer interval depends on whether the formulation, molecule, clinical setting, and patient journey have been designed to support the same therapeutic objective.
Multiple Routes to Therapeutic Duration
There is no single technical pathway to a long-acting product. Some formulations create a reservoir of drug at the administration site, from which the active ingredient dissolves or diffuses gradually. Others entrap the drug in biodegradable polymers that control release as water enters the matrix and the material erodes. Implantable systems can provide still longer delivery intervals by storing a larger drug payload within a structure engineered for sustained diffusion, degradation, or both.
The properties of the active pharmaceutical ingredient influence which of these approaches may be practical. A poorly water-soluble drug may be suitable for a suspension in which slow particle dissolution supports prolonged exposure. A potent molecule that requires only a small dose may fit within an implant or concentrated injectable depot more readily than a less potent drug that must be delivered in gram-scale quantities. Polymer-based systems add another set of variables, including polymer composition, molecular weight, degradation rate, drug–polymer interactions, and the physical structure of the finished product.
Developers can also extend therapeutic duration without creating a depot. Inclisiran uses RNA interference to reduce production of proprotein convertase subtilisin/kexin type 9, supporting a maintenance schedule of one dose every six months after the initial and three-month doses. Once-weekly insulin icodec provides another model in which the therapeutic molecule itself has been engineered to support a longer dosing interval. These products belong within the long-acting landscape even though their duration does not depend primarily on slow release from a local delivery matrix.3,4
Platform selection therefore requires more than matching a drug to a favored delivery technology. Experimental work with a highly hydrophobic antiretroviral evaluated active pharmaceutical ingredient suspensions, ionic liquids, and subdermal implants as separate approaches to achieving sustained delivery.5 The study illustrates how formulation strategy can be adapted around solubility, dose, loading, and target duration rather than assuming that one architecture will suit every molecule.
The desired treatment interval also matters. Extending activity from one day to one week may be accomplished through molecular engineering, while a six-month or annual product may require a depot or implant capable of holding and releasing a much larger amount of drug. Each additional increment of duration can intensify the demands placed on drug loading, release control, stability, and administration. The clinically meaningful target is not necessarily the longest interval that can be achieved, but the interval that best aligns therapeutic performance with a realistic delivery system and treatment pathway.
Infectious Disease: From Daily Treatment to Extended Prevention
HIV has provided some of the clearest demonstrations of how long-acting therapy can move beyond simplifying an existing regimen. Monthly injectable cabotegravir and rilpivirine maintained viral suppression comparably to standard oral therapy in adults whose HIV was already suppressed, establishing that ongoing treatment could be delivered through scheduled injections rather than daily tablets in an appropriate population.6
The larger conceptual shift has occurred in prevention. Pre-exposure prophylaxis requires protection to be maintained before an exposure occurs, which makes the consistency of dosing especially important. In HPTN 083, long-acting cabotegravir was superior to daily oral tenofovir disoproxil fumarate–emtricitabine for preventing HIV infection among cisgender men and transgender women who have sex with men. The result demonstrated that an extended dosing interval could support not only maintenance therapy but also a preventive strategy intended to provide protection across a defined period.7
Twice-yearly lenacapavir extends this model further. In PURPOSE 1, no participant assigned to twice-yearly lenacapavir acquired HIV, providing evidence that prevention could be organized around two scheduled administrations per year rather than daily oral dosing. The World Health Organization subsequently recommended injectable lenacapavir as an additional pre-exposure prophylaxis option, illustrating how long-acting approaches can progress from formulation and clinical development into public-health implementation.8,9
These examples do not mean that administration frequency is the only determinant of preventive effectiveness. Access to testing, clinic capacity, appointment attendance, follow-up, and management of delayed or missed doses remain important. Long-acting prevention shifts some of the responsibility from daily individual behavior to a system of scheduled care. That can reduce one type of burden while increasing the importance of reliable clinical infrastructure.
Research in tuberculosis shows both the appeal of this model and the distance between preclinical promise and established clinical use. An experimental long-acting rifabutin formulation maintained drug exposure for an extended period and demonstrated preventive and therapeutic activity in mice.10 The work suggests that sustained delivery could eventually support tuberculosis prevention or treatment, but it does not establish efficacy in humans.
The distinction is important because infectious disease applications can pose risks that differ from those in chronic noncommunicable diseases. If drug concentrations persist after the intended therapeutic period and fall below effective levels, the resulting pharmacokinetic tail may create a prolonged interval of subtherapeutic exposure. The acceptable duration, release profile, and follow-up strategy must therefore be considered in relation to the pathogen, mechanism of action, resistance risk, and availability of alternative therapy.
Psychiatry: A Useful Tool, Not an Automatic Solution
Long-acting antipsychotics provide a more complicated picture of clinical value. Scheduled injections can confirm that a dose was administered, which may help clinicians distinguish between inadequate drug response and a failure to receive treatment. They can also reduce the frequency with which a patient must initiate medication use and create regular points of contact with the care team.
Observational evidence has associated long-acting injectable antipsychotic use with lower all-cause mortality and suicide risk among patients with newly diagnosed schizophrenia. Such findings suggest that long-acting treatment may provide meaningful benefits in certain populations and care settings, although the observational design does not establish that the formulation alone caused the difference. Patient selection, clinical follow-up, disease severity, healthcare access, and other factors may contribute to the observed outcomes.11
Randomized evidence reinforces the need for restraint. In a trial involving patients with unstable schizophrenia, long-acting risperidone was not superior to oral antipsychotic treatment for hospitalization, symptoms, quality of life, or adherence to assigned therapy. The injectable treatment also produced more adverse events at the injection site and more neurologic adverse effects.12
The contrast between these sources does not make the evidence incoherent. It shows that changing the dosage form does not remove the social, clinical, and therapeutic factors that influence psychiatric outcomes. A patient may discontinue treatment because of adverse effects, lack of perceived benefit, logistical barriers, mistrust, or a poor relationship with the care team. An injection can confirm administration once it occurs, but it cannot ensure that a patient will return for the next appointment or remain engaged in care.
Long-acting antipsychotics are therefore best understood as tools within a larger treatment system. Their value may be greatest when the product, dosing interval, monitoring plan, and care environment fit the needs of a clearly defined population. Framing them simply as a solution to nonadherence risks overlooking why treatment was interrupted and what support will be required to sustain it.
Oncology: Sustaining Established Therapeutic Strategies
Long-acting delivery has been part of oncology practice for decades, particularly in endocrine-responsive cancers. Leuprolide depot products are available at one-, three-, four-, and six-month dosing intervals for advanced prostate cancer. These formulations provide continuous release of an established gonadotropin-releasing hormone agonist over a defined period, allowing androgen suppression to be maintained without monthly administration in every case.13
The same principle has been evaluated in breast cancer. A six-month leuprolide acetate depot adequately suppressed ovarian function in a prospective study of premenopausal patients receiving endocrine treatment for hormone receptor–positive breast cancer.14 The formulation extended the interval between administrations while preserving the intended physiological intervention.
Lanreotide offers a related but distinct example. The depot is administered every four weeks for gastroenteropancreatic neuroendocrine tumors and carcinoid syndrome, sustaining exposure to a somatostatin analog used to control disease or hormone-mediated symptoms.15
These products illustrate a mature application of long-acting technology. The formulation does not create a new anticancer mechanism. Instead, it sustains an established therapeutic strategy and reduces the number of administrations needed to maintain it. That distinction matters when considering the evidence. The available sources support continued endocrine or receptor-mediated intervention over longer intervals, but they do not justify attributing improved survival specifically to the extended-release dosage form.
The oncology experience also highlights the importance of alignment with routine care. Patients may already attend clinics for imaging, laboratory testing, infusions, or specialist visits, which can make periodic depot administration compatible with existing treatment pathways. Longer intervals may reduce the number of dedicated visits for a particular medicine, but the practical value will depend on how that schedule interacts with the rest of the patient’s care.
As long-acting technologies expand into other areas of oncology, developers will need to distinguish between drugs for which sustained exposure supports the mechanism and those for which dose timing, treatment holidays, rapid adjustment, or combination scheduling require greater flexibility. A long interval may be valuable for one endocrine therapy and inappropriate for a cytotoxic or targeted agent whose dose must be modified quickly in response to toxicity.
Chronic Disease: Expanding Beyond Conventional Depots
Chronic cardiovascular and metabolic diseases broaden the definition of long-acting treatment further. In these settings, the strategy may depend less on a visible depot and more on durable molecular activity or an extended half-life.
Inclisiran is a small interfering RNA therapeutic that reduces hepatic production of proprotein convertase subtilisin/kexin type 9. In two phase III trials, a schedule consisting of an initial dose, a second dose at three months, and subsequent dosing every six months reduced low-density lipoprotein cholesterol by approximately 50%.3
This approach separates the duration of therapeutic effect from the continued presence of a concentrated depot at the injection site. The dosing interval derives from the persistence of the biological mechanism initiated by the therapy. It also shifts lipid-lowering treatment from a daily action to an intermittent intervention that can be integrated into periodic healthcare visits.
Once-weekly insulin icodec represents another route to duration. In insulin-naive adults with type 2 diabetes, weekly icodec produced greater glycated hemoglobin reduction than daily insulin glargine U100 in a phase IIIa trial. The product illustrates how molecular engineering can reduce dosing frequency for a therapy traditionally administered every day.4
These examples show why long-acting therapeutics should not be treated as a narrow formulation category. A biodegradable microsphere, an injectable suspension, a gene-silencing therapy, and a half-life-extended protein may have little in common from a manufacturing perspective, yet each can reorganize treatment around less frequent administration.
The clinical implications also differ. A depot may release drug continuously according to material and physiological processes, while a long-lived biologic may remain active because of slow clearance or binding behavior. An RNA interference therapeutic may continue to affect target production after circulating drug concentrations decline. Monitoring, dose adjustment, missed-dose management, and the consequences of prolonged activity must therefore be designed around the specific mechanism rather than inferred from the dosing interval alone.
The Formulation and Manufacturing Problem Behind the Promise
Long duration can be difficult to achieve without compromising another attribute of the product. Extending release may require more drug, a larger depot, slower polymer degradation, or greater resistance to dissolution. Those changes can affect injection volume, viscosity, needle size, local tolerability, release variability, and manufacturability.
Drug loading is a central constraint. A formulation intended to provide several months of therapy must contain enough active ingredient to cover that interval. Increasing concentration can reduce injection volume, but it may also increase viscosity or create a suspension that cannot pass through a clinically acceptable needle. Larger particles or crystals may dissolve more slowly, yet their size distribution and morphology must remain consistent if release behavior is to be reproducible.
An experimental self-aggregating microcrystal platform illustrates the effort to balance these competing demands. The system achieved a concentration of 293 mg/mL and could be administered through needles smaller than 25 gauge while supporting prolonged release in rodents. The work remains preclinical, but it demonstrates why concentration, syringeability, needle gauge, and duration must be optimized together rather than sequentially.16
Polymeric products add further complexity. Release may occur through drug diffusion, polymer erosion, or a combination of the two. Drug properties, polymer properties, product microstructure, and manufacturing conditions can all affect the final profile. Even formulations with similar compositions may perform differently when produced through different processes, making scale-up and technology transfer particularly consequential.1,17
These relationships also complicate analytical development. A conventional tablet may release its drug over minutes or hours, while a long-acting product may continue releasing for weeks or months. Waiting for a real-time release test to finish can be impractical during development or routine quality control. Accelerated methods must shorten the test while preserving a meaningful relationship to actual product behavior.
Bioequivalence poses another challenge. For complex long-acting formulations, small differences in particle characteristics, polymer properties, or internal structure can alter the shape of the concentration–time profile even when the qualitative composition appears similar. Regulators and developers must determine which in vitro measurements are sufficiently sensitive to detect clinically relevant differences and how those measurements relate to in vivo performance.1
Machine-learning models may help developers navigate this multidimensional design space. Models trained on drug and polymer properties have been used to predict release profiles and guide the design of polymeric long-acting injectables. Their value lies in focusing experimental work and identifying relationships that may be difficult to derive intuitively. They do not eliminate the need for physical testing, process understanding, or clinical confirmation.17
Duration Creates New Clinical and Regulatory Risks
The persistence that makes a long-acting therapy attractive can also limit the ability to respond when circumstances change. A daily oral medicine can often be stopped immediately, even though its effects may not disappear at once. A nonremovable depot may continue releasing drug for weeks or months after administration.
That constraint becomes important if the patient experiences an adverse reaction, develops a contraindication, becomes pregnant, or needs to transition to another therapy. Experimental removable implants have been designed in part to permit treatment termination under such circumstances. Removability can add control, but it also introduces the need for placement and removal procedures, device localization, mechanical integrity, and training.18
Long persistence can also create a pharmacokinetic tail. After concentrations fall below the therapeutic range, low-level exposure may continue until the product has fully released or the drug has been eliminated. This may be especially consequential for anti-infective agents, where subtherapeutic exposure can complicate the management of infection or resistance risk. The release profile must therefore account for both the period of intended treatment and the decline that follows it.18
Dose adjustment may also be slower and less precise. A clinician can change the next scheduled administration, but cannot necessarily reduce the dose already present in a depot. Developers must select candidates with therapeutic windows and safety profiles compatible with this reduced flexibility. Early clinical studies also require cautious dose escalation because each administration may expose participants for an extended period.
Regulatory evaluation must address these characteristics directly. A long-acting product requires evidence that its release profile is controlled, reproducible, and clinically appropriate. Manufacturing changes that would be minor for a simpler dosage form may alter release kinetics, local tissue response, or systemic exposure. Product development must connect material attributes and process parameters to in vitro release and, ultimately, to pharmacokinetic and clinical performance.
Designing Around the Treatment Journey
The most useful starting question for a long-acting development program is not how long a drug can be made to last. It is what a longer interval is intended to accomplish.
A preventive product may need to provide reliable protection across periods when exposure cannot be predicted. A psychiatric product may need to combine a manageable injection interval with regular contact between the patient and care team. An oncology depot may need to sustain hormonal suppression while fitting into a broader schedule of monitoring and treatment. A long-acting therapy for chronic disease may need to reduce frequent self-administration without making dose adjustment or safety management impractical.
Those objectives shape the target product profile. Developers must define the desired duration, acceptable administration route, maximum injection volume, likely site of care, monitoring requirements, missed-dose strategy, and need for reversibility. They must also consider who will administer the product, how it will be stored, whether it can be transported easily, and how patients will transition onto and off the therapy.
Duration should therefore be treated as a systems-level design variable. Extending exposure affects formulation, device selection, manufacturing, clinical protocols, patient education, appointment scheduling, pharmacovigilance, and regulatory strategy. Decisions made to improve one dimension can create pressure elsewhere. Higher loading can reduce volume but increase viscosity. A longer interval can reduce dosing events but delay dose adjustment. Clinic administration can confirm receipt of therapy but increase dependence on healthcare access.
Long-acting therapeutics have already moved well beyond a narrow effort to improve adherence. They are enabling extended HIV prevention, supporting sustained endocrine therapy in oncology, reducing the frequency of lipid-lowering treatment, and opening new possibilities for proteins, RNA therapeutics, implants, suspensions, and polymeric systems. Their continued expansion will depend on selecting clinical problems for which duration provides a genuine therapeutic or operational advantage.
The strongest products will not simply remain active for longer. They will use that duration to create a treatment model that is clinically appropriate, technically feasible, manufacturable at scale, and workable for the patients and healthcare systems expected to use it.
References
1. “FY2015 Regulatory Science Research Report: Long-Acting Injectable Formulations.” U.S. Food and Drug Administration. 9 May 2017.
2. Park, Haesun, Andrew Otte, and Kinam Park, “Evolution of Drug Delivery Systems: From 1950 to 2020 and Beyond.” Journal of Controlled Release. 342: 53–65 (2022).
3. Ray, Kausik K, et al. “Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.” The New England Journal of Medicine. 382: 1507–1519 (2020).
4. Rosenstock, Julio, et al. “Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.” The New England Journal of Medicine. 389: 297–308 (2023).
5. Akhavein, Nima, et al. “Parenteral Platforms for Tunable, Long-Acting Administration of a Highly Hydrophobic Antiretroviral Drug.” Scientific Reports. 14: 11573 (2024).
6. Swindells, Susan, et al. “Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.” The New England Journal of Medicine. 382: 1112–1123 (2020).
7. Landovitz, Raphael J, et al. “Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.” The New England Journal of Medicine. 385: 595–608 (2021).
8. Bekker, Linda-Gail, et al. “Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.” The New England Journal of Medicine. 391: 1179–1192 (2024).
9. “WHO Recommends Injectable Lenacapavir for HIV Prevention.” World Health Organization. 14 Jul. 2025.
10. Kim, Manse, et al. “A Long-Acting Formulation of Rifabutin Is Effective for Prevention and Treatment of Mycobacterium tuberculosis.” Nature Communications. 13: 4455 (2022).
11. Huang, Cheng-Yi, Su-Chen Fang, and Yu-Hsuan Joni Shao. “Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics and Suicide and All-Cause Mortality in Patients With Newly Diagnosed Schizophrenia.” JAMA Network Open. 4: e218810 (2021).
12. Rosenheck, Robert A, et al. “Long-Acting Risperidone and Oral Antipsychotics in Unstable Schizophrenia.” The New England Journal of Medicine. 364: 842–851 (2011).
13. “LUPRON DEPOT (Leuprolide Acetate) Kit.” DailyMed, U.S. National Library of Medicine. Accessed 16 Jun. 2026.
14. Wu, Zhen-Yu, et al. “Effectiveness of a 6-Month 22.5-mg Leuprolide Acetate Depot Formulation With Tamoxifen for Postoperative Premenopausal Estrogen Suppression in Hormone Receptor-Positive Breast Cancer.” Frontiers in Oncology. 11: 665426 (2021).
15. “SOMATULINE DEPOT (Lanreotide Acetate) Injection.” DailyMed, U.S. National Library of Medicine. Accessed 16 Jun. 2026.
16. Feig, Vivian R, et al. “Self-Aggregating Long-Acting Injectable Microcrystals.” Nature Chemical Engineering. 2: 209–219 (2025).
17. Bannigan, Pauric, et al. “Machine Learning Models to Accelerate the Design of Polymeric Long-Acting Injectables.” Nature Communications. 14: 35 (2023).
18. Benhabbour, S Rahima, et al. “Ultra-Long-Acting Tunable Biodegradable and Removable Controlled Release Implants for Drug Delivery.” Nature Communications. 10: 4324 (2019).
